Glimestar-PM1 Tablet ER
Glimestar-PM1 Tablet ER
Glimepiride (1mg) + Metformin (500mg) + Pioglitazone (15mg)
Cheaper alternative availability
Already at the Best Price
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
About This Medicine
Product description & overview
Glimestar-PM1 Tablet ER is a combination oral antidiabetic medication containing Glimepiride 1mg, Metformin 500mg, and Pioglitazone 15mg, formulated as an extended-release tablet for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. Pioglitazone, a thiazolidinedione, further enhances insulin sensitivity in adipose tissue, muscle, and the liver by activating peroxisome proliferator-activated receptor-gamma (PPAR-γ). The extended-release formulation ensures a sustained therapeutic effect, promoting better patient compliance through once-daily dosing. Glimestar-PM1 is indicated for patients inadequately controlled on diet and exercise alone or on monotherapy with any of the individual components. It is essential to monitor blood glucose levels regularly and adjust the dosage accordingly to minimize the risk of hypoglycemia and other adverse effects. Caution is advised in patients with renal or hepatic impairment, heart failure, or a history of lactic acidosis. This combination therapy offers a multifaceted approach to glycemic management by targeting different pathophysiological defects in type 2 diabetes.
Active composition
Glimepiride 1 mg
+2 more active ingredients
About Glimepiride
Glimepiride is an oral hypoglycemic agent used to manage blood sugar levels in patients with type 2 diabetes mellitus. It works by stimulating the pancreas to release more insulin, thereby lowering blood glucose levels and preventing the symptoms associated with diabetes. Glimepiride is often prescribed alongside diet and exercise to enhance glycemic control and reduce the risk of diabetes-related complications, such as kidney damage and neuropathy. In summary, Glimepiride is an essential medication for controlling blood sugar levels in type 2 diabetes patients.
How It Works
Glimepiride stimulates insulin secretion from pancreatic beta cells and enhances insulin sensitivity in peripheral tissues, facilitating glucose uptake and lowering blood sugar levels.
All Active Ingredients
Pioglitazone
Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-γ), enhancing insulin sensitivity and glucose metabolism.
Metformin
Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.
Dosage & How to Use
Dosage information not available. Please consult your doctor or pharmacist.
Safety Advice
Important precautions
Side Effect Occurrence
Based on clinical trials and patient reports.
Overall Tolerance
Most patients tolerate well
Common Side Effects
Safety Advice
Alcohol
It is unsafe to consume alcohol with Glimestar-PM1 Tablet ER.
High Risk
Pregnancy
Glimestar-PM1 Tablet ER may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Medical Advice
Driving
Your ability to drive may be affected if your blood sugar is too low or too high. Do not drive if these symptoms occur.
Exercise Caution
Liver
Glimestar-PM1 Tablet ER should be used with caution in patients with liver disease. Dose adjustment of Glimestar-PM1 Tablet ER may be needed. Please consult your doctor. Use of Glimestar-PM1 Tablet ER is not recommended in patients with severe liver disease.
Regular Checkup
Breastfeeding
Glimestar-PM1 Tablet ER is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Consult Doctor
Kidney
Glimestar-PM1 Tablet ER should be used with caution in patients with kidney disease. Dose adjustment of Glimestar-PM1 Tablet ER may be needed. Please consult your doctor. Use of Glimestar-PM1 Tablet ER is, however, not recommended in patients with severe kidney disease. Regular monitoring of kidney function test is advisable while you are taking this medicine.
Regular Checkup
Customer Reviews
0 reviews for Glimestar-PM1 Tablet ER
